Boston Scientific Begins Expansion of S-ICD System in Asia
April 11, 2014 — Boston Scientific Corp. has expanded the launch of its S-ICD (subcutaneous implantable cardioverter-defibrillator) system into parts of Asia. The first implant of the S-ICD in Asia was performed in Hong Kong by Hung-Fat Tse, professor of cardiovascular medicine, University of Hong Kong, and department of medicine, Queen Mary Hospital in Pokfulam, Hong Kong, under the proctorship of Dr. Martin Stiles, director of electrophysiology, Waikato Hospital in Hamilton, New Zealand.
Recent estimates show that almost 2 million people in the Asia Pacific region are at risk of sudden cardiac arrest (SCA) but are currently unprotected. The S-ICD system can provide protection for at-risk patients, leaving the heart and blood vessels untouched, and offering patients a compelling alternative to transvenous implantable cardioverter defibrillators (TV-ICDs), which require leads to be placed in the heart. Implantation of the S-ICD system uses anatomical landmarks without the need for fluoroscopy.
"The S-ICD system is a revolutionary and unique option for patients at risk of SCA," said Tse. "I envision the S-ICD system to be the first-choice solution for eligible patients because it provides a less invasive therapy with performance as good as TV-ICDs."
This defibrillation therapy has been commercially available in Europe since 2009 and was approved in the United States in late 2012. Boston Scientific continues to expand the availability of this unique therapy for patients and physicians around the world.
"Most of the world's population resides in Asia, which includes a high portion of unprotected patients at risk of SCA. The S-ICD system highlights Boston Scientific's commitment to bring meaningful innovation to patients and physicians in this critically important region," said Supratim Bose, executive vice president and president for Asia, Middle East and Africa, Boston Scientific.
The S-ICD does not have regulatory approval in China, Japan or South Korea and is not available for sale in those countries.
For more information: www.bostonscientific.com
More like this
- Boston Scientific Begins Expansion of S-ICD System in Asia
- Long-Term Data Underscore Safety, Efficacy of Boston Scientific’s S-ICD System
- Boston Scientific’s Emblem S-ICD System Receives FDA, CE Mark Approval
- FDA Panel Recommends Approval of Cameron Health's Subcutaneous S-ICD System
- Ten-Year-Old Boy is Florida’s First Pediatric Patient to Receive S-ICD